Drug Profile
Research programme: motilin receptor antagonists - Ocera Therapeutics
Alternative Names: TZP-201; TZP-202Latest Information Update: 14 Dec 2017
Price :
$50
*
At a glance
- Originator Tranzyme
- Developer Ocera Therapeutics; Tranzyme
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Motilin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diarrhoea; Gastrointestinal disorders
- Discontinued Non-ulcer dyspepsia
Most Recent Events
- 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt plc
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diarrhoea(Chemotherapy-induced) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (PO)